Naomi Eichenbaum | VP, IR |
Eric Dube | President, CEO & Director |
Jula Inrig | Chief Medical Officer |
Christopher Cline | CFO |
Peter Heerma | Chief Commercial Officer |
William Rote | SVP, Research & Development |
Gregory Harrison | Bank of America Merrill Lynch |
Maurice Raycroft | Jefferies |
Joseph Schwartz | SVB Securities |
Lachlan Hanbury-Brown | William Blair & Company |
Antonio Arce | H.C. Wainwright & Co. |
Carter Gould | Barclays Bank |
Liisa Bayko | Evercore ISI |
Alexander Thompson | Stifel, Nicolaus & Company |
Guyn Kim | Piper Sandler & Co. |
Laura Chico | Wedbush Securities |
Good day, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update. Today's conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi. Thank you.